Mesothelioma: Increasing Life Expectancy with New Treatments.

For decades, a mesothelioma diagnosis meant a prognosis measured in months — typically six to twelve. That reality, unchanged for a generation, has begun to shift. Not uniformly, not for every patient, but meaningfully — driven by immunotherapy, better surgical selection, and a growing ecosystem of clinical trials.

A sixteen-year stalemate.

Between 2004 and 2020, there were no new first-line drug approvals for mesothelioma in the United States. The standard of care — pemetrexed combined with cisplatin — had been established in 2004 on the strength of a modest survival benefit over cisplatin alone. It became the backbone of mesothelioma chemotherapy for the next sixteen years, and while thoracic surgeons refined techniques and radiation oncologists gained precision tools, the fundamental trajectory of the disease barely budged.

Median survival hovered at roughly twelve to eighteen months for pleural mesothelioma under optimal care. The phrase "new therapeutic options" in the mesothelioma literature was, for much of this period, aspirational.

The 2020 inflection point.

That changed on October 2, 2020, when the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as first-line treatment for unresectable pleural mesothelioma. It was the first new drug approval in the disease in more than a decade and a half, and the mechanism was fundamentally different from chemotherapy: rather than poisoning rapidly dividing cells, checkpoint inhibitors release the brakes on the immune system so that the body itself recognizes and attacks the cancer.

"This was the first regimen in sixteen years to meaningfully change what we could offer patients."

— Commentary on the CheckMate-743 approval

What the CheckMate-743 data showed.

The pivotal trial behind the 2020 approval — CheckMate-743 — compared the nivolumab plus ipilimumab combination to the standard pemetrexed plus platinum-based chemotherapy. The headline result was a median overall survival of 18.1 months in the immunotherapy arm versus 14.1 months in the chemotherapy arm.

But the more compelling story was in the long-term follow-up. At three years, 23% of patients on dual immunotherapy were still alive, compared to 15% on chemotherapy. At four years, the numbers were 16.8% versus 10.7%. The three-year progression-free survival rate was 14% on immunotherapy compared to just 1% on chemotherapy — a difference that points to something real about how immune-based treatment behaves differently from traditional cytotoxic therapy. For a subset of patients, the response is durable in a way that chemotherapy alone rarely achieved.

The benefit was particularly striking in patients with non-epithelioid histology (the sarcomatoid and biphasic subtypes), which historically responded poorly to chemotherapy. In that group, immunotherapy produced meaningful survival extensions where chemotherapy had essentially nothing to offer.

Keytruda joins the frontline.

In September 2024, the FDA approved a second immunotherapy-based first-line regimen: pembrolizumab (Keytruda) combined with chemotherapy for unresectable pleural mesothelioma. The combination produced a 63% response rate and a three-year survival rate of 25%, compared to 40% and 17% respectively for chemotherapy alone. For the first time, mesothelioma patients had two distinct first-line options with different toxicity profiles.

A year later, in November 2025, the FDA approved Keytruda Qlex — a subcutaneous version of pembrolizumab. What sounds like a minor logistical change matters substantially for patients: infusion appointments that once required hours in a chair now take minutes by injection, dramatically improving quality of life during long treatment courses.

Peritoneal: HIPEC's outsize impact.

The peritoneal form of mesothelioma — accounting for roughly 10–15% of cases and arising in the lining of the abdomen rather than the chest — has followed a different but equally encouraging trajectory. The transformative advance here isn't a drug; it's a surgical approach called cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, or CRS/HIPEC.

In CRS/HIPEC, a surgeon removes as much visible tumor as possible and then circulates heated chemotherapy directly through the abdominal cavity — concentrating the drug where the disease lives while largely sparing the rest of the body. In carefully selected patients at experienced high-volume centers, five-year survival rates of 40% to 65% have been reported — a dramatic departure from the outcomes seen with systemic chemotherapy alone.

The critical qualifier: HIPEC is technically demanding and carries meaningful surgical risk. Only roughly 20 to 30 centers in the United States perform it at volumes associated with optimal outcomes, and evidence consistently shows that institutional HIPEC experience correlates directly with patient survival. Where you have this procedure is as important as whether you have it.

What still determines outcomes.

Mesothelioma prognosis is not a single number. It's a distribution, and where a particular patient sits in that distribution depends on several factors — some modifiable, some not:

• Histologic subtype. Epithelioid mesothelioma generally carries a better prognosis than sarcomatoid or biphasic subtypes, though immunotherapy has narrowed that gap somewhat.
• Stage at diagnosis. Earlier-stage disease opens more treatment options, including surgical candidacy. Unfortunately, mesothelioma is often diagnosed at later stages because early symptoms can be vague.
• Performance status. A patient's overall health and functional capacity at diagnosis meaningfully affects treatment tolerance and outcomes — a factor that makes care before symptoms become severe particularly valuable.
• Treatment at a specialty center. High-volume centers consistently produce better outcomes than general oncology practices, especially for surgery and HIPEC.
• Access to clinical trials. For patients who are or may become candidates, trial enrollment opens access to next-generation therapies (CAR-T, BAP1-targeted drugs, TROP2 ADCs) years before they reach general practice.
• Biomarker status. PD-L1 expression, BAP1 mutation status, and other molecular features are increasingly influencing treatment decisions and may predict who benefits most from specific regimens.